Small Molecules

10 Nov 2021 Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
10 Nov 2021 Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021
10 Nov 2021 CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease
10 Nov 2021 Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
08 Nov 2021 Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor
08 Nov 2021 Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections
06 Nov 2021 GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
05 Nov 2021 Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study
05 Nov 2021 Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
05 Nov 2021 Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
04 Nov 2021 Kazia Enrols First Patient to EVT801 Phase I Clinical Trial
04 Nov 2021 NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study
04 Nov 2021 Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy® (ipilimumab) for Treatment of Metastatic Endometrial Cancer
04 Nov 2021 Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
04 Nov 2021 Tranquis Therapeutics Presents Positive Preclinical Data on TQS-168 for the Treatment of ALS at Neuroscience 2021 Annual Meeting
03 Nov 2021 Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis
03 Nov 2021 BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies
02 Nov 2021 Amylyx Pharmaceuticals Submits New Drug Application (NDA) for AMX0035 for the Treatment of ALS
01 Nov 2021 HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
01 Nov 2021 Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021
01 Nov 2021 Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH
01 Nov 2021 Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib Study of Its Novel PARP Inhibitor (RP12146) in Patients With Advanced Solid Tumors
01 Nov 2021 Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition as Novel Approach for the Treatment of Autoimmune and Inflammatory Diseases
01 Nov 2021 Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874
01 Nov 2021 Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up